Abstract:Background: Models to predict survival of persons with plasma cell myeloma are mostly use clinical and laboratory co-variates including cytogenetics and mutation topography. These models have AUCs of 0.55 to 0.77 indicating considerable inaccuracy. We tested whether data of plasma cell metabolism might improve prediction accuracy. Methods: RNA matrix, clinical and laboratory data from datasets GSE13633 (training cohort) and GSE57317, GSE24080 and GSE2658 (validation cohorts) were downloaded from the Gene Expression Omnibus (GEO) database. Genes regulating plasma cell metabolism correlating with survival were identified in uni-variable Cox regression analyses and a metabolic risk score built by Lasso Cox regression analysis. Survivals was compared by Kaplan-Meier curves with log-rank tests. Prediction accuracy of the metabolic risk score was quantified by time-dependent receiver operating characteristic (ROC) curves and the area under the curve. A nomogram was developed including metabolic risk score and ISS stage. Enriched pathways in different metabolic risk score cohorts were evaluated by gene set enrichment analyses (GSEA). We interrogated validity of 3 genes with the largest risk coefficients in vitro using small molecule inhibitors to test effects on cell proliferation and apoptosis by CCK-8 and multi-parameter flow cytometry (MPFC). Results: 7 genes regulating plasma cell metabolism with high risk coefficients were used to develop a metabolic risk score. The score had robust predictive performance with AUCs for 3-year survival in the 4 cohorts of 0.71 [95% Confidence Interval, 0.65, 0.79], 0.88 [0.71, 1.03], 0.70 [0.63,0.76] and 0.71 [0.65, 0.79]. Subjects in the high-risk cohort had worse 3-year survivals compared with those in the low-risk cohort (62% [55, 68%] vs. 85% [80, 90%], P < 0.001; 54% [33, 76%] vs. 92% [82, 102%], P <0.001; 58% [52, 65%] vs. 77% [71, 82%], P <0.001; and 51% [38, 64%] vs. 74% [62, 85%], P <0.001). The metabolic risk score remained an independent prognostic factor for survival in multi-variable regression analyses. A nomogram combining metabolic risk score with ISS score increased prediction accuracy of 5-year survival (AUCs of 0.72 [0.69,0.81] vs. 0.66 [0.60, 0.72]; P = 0.015). In GSEA most gene enrichment pathways in high-risk cohort were metabolism-related. In vitro, the results showed that the three small molecule inhibitors combined with bortezomib had a synergistic inhibitory effect on the growth of myeloma cells H929, MM.1S, U266B1 and RPMI 8226, with an effective synergistic CI value; and enhanced the apoptosis of myeloma cell lines effect. Conclusion: A risk score based on expression of genes involved in plasma cell metabolism predicted survival and significantly improved prediction accuracy of the ISS score. Predictions based on gene expression were validated in vitro. Keywords GEO, plasma cell myeloma, metabolism, prognostic model Disclosures No relevant conflicts of interest to declare.

Decision tree algorithm to predict mortality in incurable cancer: a new prognostic model

A new prediction model for assessing the clinical outcomes of ICU patients with community-acquired pneumonia: a decision tree analysis.

A Multifactor Model for Predicting Mortality in Critically Ill Patients: A Multicenter Prospective Cohort Study

Prognostic Machine Learning Models for First-Year Mortality in Incident Hemodialysis Patients: Development and Validation Study.

New Prognostic Risk Score for Predicting In-Hospital Mortality in Geriatric Patients Undergoing Colorectal Cancer Surgery: U.S. Nationwide Inpatient Sample Analysis

A Novel Decision Tree Model for Predicting the Cancer-Specific Survival of Patients with Bladder Cancer Treated with Radical Cystectomy

Derivation and validation of a prognostic model to predict mortality in patients with advanced chronic kidney disease

Comparing Clinician Estimates versus a Statistical Tool for Predicting Risk of Death within 45 Days of Admission for Cancer Patients

Predicting Disease-Specific Survival for Patients with Primary Cholangiocarcinoma Undergoing Curative Resection by Using a Decision Tree Model

Development and Validation of a Survival Prediction Model for Patients with Pancreatic Cancer

Development and validation of a prediction model for mortality in critically ill COVID-19 patients

A Decision Tree Model to Predict Liver Cirrhosis in Hepatocellular Carcinoma Patients: a Retrospective Study.

A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma

Development and Validation of an Interpretable Machine Learning Model for Early Prognosis Prediction in ICU Patients with Malignant Tumors and Hyperkalemia

The Utility of Multiple Clinical Variables in Predicting Survival Outcome for Patients with Rectal Cancer: an Integrated Regression and Retrospective Cohort Analysis.

Development and validation of a prognostic model for patients with hepatorenal syndrome: A retrospective cohort study

Predicting cancer patient mortality within 30 days of radiotherapy consultation to inform palliative radiotherapy fractionation decisions

A model predicting short-term mortality in patients with advanced liver cirrhosis and concomitant infection.

An Accurate Prognostic Survival Model of Survival Based on Expression of Genes Involved in Plasma Cell Metabolism

Development and Validation of a New Prognostic Model for Predicting Survival Outcomes in Patients with Acute-on-chronic Liver Failure

Development and validation of a survival prediction model for patients with advanced non-small cell lung cancer based on LASSO regression